BioMed Research International

BioMed Research International / 2014 / Article

Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”

  • Benjamin D. Kessler | Robert S. Hoffman |
  •  Article ID 705754 |
  •  Published 11 Mar 2014

Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”

  • Abbas Aghabiklooei | Hossein Hassanian-Moghaddam | Nasim Zamani |
  •  Article ID 752902 |
  •  Published 22 Feb 2015
  • | View Article

Letter to the Editor | Open Access

Volume 2014 |Article ID 705754 | https://doi.org/10.1155/2014/705754

Benjamin D. Kessler, Robert S. Hoffman, "Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”", BioMed Research International, vol. 2014, Article ID 705754, 1 page, 2014. https://doi.org/10.1155/2014/705754

Comment on “Effectiveness of Naltrexone in the Prevention of Delayed Respiratory Arrest in Opioid-Naive Methadone-Intoxicated Patients”

Academic Editor: Francesco Dondero
Received31 Dec 2013
Accepted22 Jan 2014
Published11 Mar 2014

In the recent paper by Aghabikoolei et al. [1], the authors postulate that oral naltrexone prevents delayed respiratory depression following naloxone reversal of methadone toxicity. We would like to voice a few concerns regarding the study.

The restriction of the study to only opiate naïve patients limits its applicability. Methadone is more frequently used for the prevention of opioid withdrawal symptoms, for the maintenance of opioid abstinence, or for the treatment of chronic pain. Inherently, by the nature of access to the medication, most people who are exposed are tolerant. It seems problematic to include patients based on self- or familial account that they do not use opiates. The number of patients originally enrolled but subsequently excluded for withdrawal symptoms after naloxone administration highlights the challenges of this approach.

Additionally, the half-life of methadone is approximately 48 hours and the 50 mg of naltrexone is expected to block the effects of the methadone at the opioid receptors for approximately 24 hours. Since the patients in the naltrexone group only had a mean hospital stay of 26 hours, many of them left when they were still potentially vulnerable to delayed respiratory depression. It would be important to know if any returned for readmission or were subsequently found dead.

Abrupt and prolonged iatrogenic opioid withdrawal can be severe and life threatening [2] and should be avoided. This must be balanced by the need for ICU level care when respiratory depression is predicted. As such, the results of this study seem most applicable in unintentional ingestions in children since they are usually opiate naïve and often require transfer for PICU level care.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

  1. A. Aghabiklooei, H. Hassanian-Moghaddam, N. Zamani et al., “Effectiveness of naltrexone in the prevention of delayed respiratory arrest in opioid-naïve methadone-intoxicated patients,” BioMed Research International, vol. 2013, Article ID 903172, 7 pages, 2013. View at: Publisher Site | Google Scholar
  2. R. J. Hamilton, R. E. Olmedo, S. Shah et al., “Complications of ultrarapid opioid detoxification with subcutaneous naltrexone pellets,” Academic Emergency Medicine, vol. 9, no. 1, pp. 63–68, 2002. View at: Google Scholar

Copyright © 2014 Benjamin D. Kessler and Robert S. Hoffman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

631 Views | 318 Downloads | 1 Citation
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.